Dana Foundation

The Dana Foundation (Charles A. Dana Foundation) is a private philanthropic organization based in New York committed to advancing brain research and to educating the public in a responsible manner about research’s potential. Its goals are: (1) to develop a better understanding of the brain and its functions; (2) to speed the discovery of treatments for brain disorders; and (3) to combat the stigma of brain disorders through education.

The Foundation was founded in 1950 by Charles A. Dana, a legislator and businessman from New York State, and CEO of the Dana Corporation. He presided over the organization until 1960, but continued to participate until his death in 1975.

Edward F. Rover is the current chairman of the Foundation.[1] He served as vice-chairman of the Board of Directors of the Foundation before being elected president in 2000 and then chairman in 2009. Rover was a senior partner at White & Case, L.L.P. in New York City until December 31, 2003. Rover succeeded William Safire, who became Dana’s chairman following David Mahoney’s death in 2000.[2]

The Dana Foundation supports the Dana Alliance for Brain Initiatives and the European Dana Alliance for the Brain, nonprofit organizations of leading neuroscientists committed to advancing public awareness about the progress and promise of brain research.[3] The Dana Alliance for Brain Initiatives was officially launched in 1993, and has more than 350 members, including nine Nobel laureates. The European Dana Alliance for the Brain was established in 1997, and has more than 260 members, including five Nobel laureates, from 32 countries.

The Dana Foundation’s current area of research emphasis is in neuroscience, focusing on neuroimaging and clinical neuroscience research.[4]

David Mahoney Neuroimaging grants support research on imaging innovations that help reveal how the human brain functions normally, how disorders and injuries alter these functions, and how various therapies affect these conditions.

The Clinical Neuroscience Research grants support researchers testing promising therapies that move from animal models to a small number of human patients with devastating, currently untreatable brain diseases (first-in-human studies). Also supported are studies to develop ethical guidelines in brain research.

...
Wikipedia